Pulmonary Pharmacology & Therapeutics

Pulmonary Pharmacology & Therapeutics 由 Academic Press Inc. 出版，属中科院医学大类（2025 升级版3区）。按 OpenAlex 近年发文统计，该刊主要发表 Asthma and respiratory diseases、Respiratory and Cough-Related Research、Chronic Obstructive Pulmonary Disease (COPD) Research 等主题的论文，这 3 个主题约占 45.4%，主导子领域为 Pulmonary and Respiratory Medicine。（根据 OpenAlex 主题统计与中科院分区数据生成）

Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews.Research Areas Include:• All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary ToxicologyBefore submitting, please note the "Rules of 5" defining immediate rejection criteria of PPT:1. Out of scope: The paper should report on the use of pharmacological or toxicological studies (positive or negative) that are directly related to Pulmonary Pharmacology & Therapeutics.Immediate rejection criteria are: a) Testing of extracts or plant parts that are not characterized b) Case Reports or n=1 studies2. Too preliminary: A paper must be based on a thorough and extensive study, using proper controlsImmediate rejection criteria are: a) In vitro studies with a single dose, or very high concentration b) Single dose studies with very few animals, no dose-response studies c) No proper controls. d) Repetition or confirmation of an earlier work3. Unethical: The study must have been carried under appropriate ethical approval for the study (either animal or human).4. Inappropriate experiments or lacking essential detailImmediate rejection criteria are: a) Wrong species or lacking details on the exact number of animals/subjects used b) No details of structure if a new drug is used for the first time5. Lack of novelty: The study must represent a novel approach to the field.Immediate rejection criteria are: a) Repetition of well known data b) No advance of knowledge in the fieldNote that only manuscripts written in good English will be considered by the Editors (British usage is preferred).

摘自期刊官网 Aims & Scope

研究方向（LetPub）：医学-呼吸系统

主编 Estelle Cormet-Boyaka出版商官网

编委会国家分布：中国大陆 1 位（约 3%）；主要国家 美国 12、英国 8、意大利 7、新加坡 2、中国 1（共 35 位编委标注了国家） 编委会 ↗出版商官网 · 2026-10-01

中科院期刊分区表

数据库收录

SCIEScopusLetPub

国际期刊预警名单：各版本均未列入LetPub

不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。

影响力指标

影响因子

3.61LetPub · 2026-09-13

影响因子（出版商公布）

3.8出版商官网 · 2026-10-01

CiteScore 2026-06

5.9LetPub · 2026-09-13

CiteScore（出版商公布）

5.9出版商官网 · 2026-10-01

SJR 2026-06

0.82LetPub · 2026-09-13

SNIP 2026-06

0.77LetPub · 2026-09-13

h-index

66LetPub · 2026-09-13

h-index

95OpenAlex · 2026-10-01

i10-index

1,440OpenAlex · 2026-10-01

两年平均被引

3.27OpenAlex · 2026-10-01

自引率

2.6%LetPub · 2026-09-13

Gold OA 文章占比

20.79%LetPub · 2026-09-13

发文规模

年文章数

26LetPub · 2026-09-13

不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。

其他来源

平均审稿速度（社区反馈）

较慢,6-12周来源Elsevier官网：平均9.7周LetPub · 2026-09-13

平均录用比例（社区反馈）

较易LetPub · 2026-09-13

投稿到首次决定

16 天出版商官网 · 2026-10-01

外审后首次决定

85 天出版商官网 · 2026-10-01

投稿到接收

131 天出版商官网 · 2026-10-01

接收到发表

2 天出版商官网 · 2026-10-01

社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。

混合期刊的文章处理费仅在作者选择开放获取发表时收取；按订阅方式发表通常不收费。

费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。

摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。

出版商

Academic Press Inc.

出版国家或地区

ENGLAND

出版语言

English

出版周期

Bimonthly

创刊年份

1997

ISSN

1094-5539

电子版 ISSN

1522-9629

官方链接

• 期刊主页 ↗OpenAlex
• 投稿系统 ↗出版商官网
• 专刊 / 特刊征稿 ↗出版商官网